A Phase 3 interventional study of Insulin Efsitora Alfa and Insulin Lispro (U100) in Type 2 Diabetes and Type 2 Diabetes Treated With Insulin, sponsored by Eli Lilly and Company. Completed at 81 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing insulin efsitora alfa in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin efsitora alfa · Diabetes Mellitus, Type 2.
Among the 14 studies testing insulin efsitora alfa in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 4 that started in 2022, is one of 4 in phase 3, and was the 10th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 14 studies testing insulin efsitora alfa in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
insulin efsitora alfa: first FDA approval 2026 (ONSWIK). What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 730 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 75 across the 14 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 1 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 42nd largest by enrollment of the 232 interventional ones that give a count, is one of 11 that started in 2022, is one of 85 in phase 3, and was the 186th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing insulin efsitora alfa in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin. The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period. The study will last up to 34 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have been treated with a stable regimen of one of the following basal insulins used according to local product label with or without noninsulin diabetes therapy for at least 90 days prior to screening
Have been treated with at least twice daily dosing of one of the following insulins used according to local product label for at least 90 days prior to screening. One dose of prandial insulin must occur at the evening meal.
Acceptable noninsulin diabetes therapies may include 0 to up to 3 of the following with a stable dose for at least 90 days prior to screening
Exclusion Criteria:
Are currently receiving any of the following insulin therapies anytime in the past 90 days:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 500 units per milliliter (U/mL) Insulin Efsitora Alfa (insulin efsitora) administered subcutaneously (SC) once weekly (QW) along with 100 U/mL insulin lispro given SC with meals as needed.
Drug: Insulin Efsitora Alfa · Drug: Insulin Lispro (U100)
Participants received 100 U/mL insulin glargine administered SC once daily (QD) along with 100 U/mL insulin lispro given SC with meals as needed.
Drug: Insulin Lispro (U100) · Drug: Insulin Glargine (U100)
Administered SC
Also known as: LY3209590 and Basal Insulin-FC
Administered SC
Also known as: Humalog
Administered SC
Also known as: Basaglar
Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority]
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Baseline, Week 26
Change From Baseline in HbA1c [Superiority]
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Baseline, Week 26
Percentage of Participants Achieving HbA1c <7% Without Nocturnal Hypoglycemia
Percentage of participants achieving HbA1c \<7% without nocturnal hypoglycemia \[\<54 milligram/deciliter (mg/dL) 3.0 millimole/Liter (mmol/L)\] or severe during treatment phase up to week 26. Nocturnal hypoglycemia is a hypoglycemia event, including severe hypoglycemia, that occurs at night and presumably during sleep between midnight and 6:00 am.
Time frame: Week 26
Nocturnal Hypoglycemia Event Rate
The event rate of participant-reported clinically significant nocturnal hypoglycemia, (where glucose \<54 mg/dL (3.0 mmol/L) or severe and occurs at night and presumably during sleep between midnight and 6:00 AM), measured during treatment phase up to week 26. Group mean is reported here.
Time frame: Baseline Up To Week 26
Change From Baseline in Fasting Glucose
Change from baseline in fasting glucose measured by self-monitoring blood glucose (SMBG).
Time frame: Baseline, Week 26
Percentage of Time in Glucose Range
Percentage of Time in glucose range between 70 and 180 mg/dL (3.9 and 10.0 mmol/L), inclusive measured during the continuous glucose monitoring (CGM) session.
Time frame: Week 22 to Week 26
Percentage of Time in Hypoglycemia Range
Percentage of Time in hypoglycemia range with glucose \<54 mg/dL (3.0 mmol/L), measured by CGM.
Time frame: Week 22 to Week 26
Percentage of Time in Hyperglycemia Range
Percentage of Time in hyperglycemia range with glucose \>180 mg/dL (10.0 mmol/L), measured by CGM.
Time frame: Week 22 to Week 26
Glucose Variability Between Weeks 22 to 26
Glucose variability measured as coefficient of variation for glucose within day for 24-hour period between Week 22 and 26 was reported.
Time frame: Week 22 to Week 26
Basal Insulin Dose at Week 26
Average weekly basal Insulin Dose at Week 26 was reported.
Time frame: Week 26
Bolus Insulin Dose at Week 26
Average daily bolus Insulin Dose at Week 26 was reported.
Time frame: Week 26
Total Insulin Dose at Week 26
Average total weekly insulin dose at Week 26 was reported.
Time frame: Week 26
Basal Insulin Dose to Total Insulin Dose Ratio at Week 26
Basal insulin dose to total insulin dose ratio at Week 26 was reported.
Time frame: Week 26
Hypoglycemia Event Rate
Hypoglycemia event rate was reported. Hypoglycemia with glucose \<54 mg/dL (Level 2) or Severe Hypoglycemia (Level 3) was reported. A severe hypoglycemic event is characterized by altered mental or physical status requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions for the treatment of hypoglycemia. Group mean was reported here.
Time frame: Baseline up to Week 26
Change From Baseline in Body Weight
Change from baseline in body weight was reported.
Time frame: Baseline, Week 26
Treatment Experience for Diabetes Injection Device at Week 26 - Experience Questionnaire (DID-EQ)
The DID-EQ is a self-administered, 10-item questionnaire designed to assess participants' perceptions of diabetes injection delivery systems for diabetes. The Device Characteristic Subscale is comprised of items 1 to 7 which focus on specific characteristics of injection devices. Each item is rated on a four-point Likert scale. Scores are transformed and range from 0 to 100. Higher scores indicate more positive perceptions of injection device characteristics
Time frame: Week 26
Participants underwent a 26-week treatment period, followed by a 5-week safety follow-up period.
| Milestone | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Started | 365 | 365 |
| Received at least 1 dose of study drug | 365 | 365 |
| Completed | 348 | 344 |
| Not completed | 17 | 21 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Assigned treatment by mistake | 4 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 3 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 12 |
| Milestone | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Started | 357 | 354 |
| Completed | 352 | 349 |
| Not completed | 5 | 5 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
| Percentage of HbA1c | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] | -1.01 ± 0.0463 | -1.00 ± 0.0463 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
| Percentage of HbA1c | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Change From Baseline in HbA1c [Superiority] | -1.01 ± 0.0463 | -1.00 ± 0.0463 |
Percentage of participants achieving HbA1c \<7% without nocturnal hypoglycemia \[\<54 milligram/deciliter (mg/dL) 3.0 millimole/Liter (mmol/L)\] or severe during treatment phase up to week 26. Nocturnal hypoglycemia is a hypoglycemia event, including severe hypoglycemia, that occurs at night and presumably during sleep between midnight and 6:00 am.
| Percentage of participants | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Percentage of Participants Achieving HbA1c <7% Without Nocturnal Hypoglycemia | 38.6 | 35.9 |
The event rate of participant-reported clinically significant nocturnal hypoglycemia, (where glucose \<54 mg/dL (3.0 mmol/L) or severe and occurs at night and presumably during sleep between midnight and 6:00 AM), measured during treatment phase up to week 26. Group mean is reported here.
| Events per year | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Nocturnal Hypoglycemia Event Rate | 0.67 ± 0.112 | 1.00 ± 0.151 |
Change from baseline in fasting glucose measured by self-monitoring blood glucose (SMBG).
| milligrams per deciliter (mg/dL) | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Change From Baseline in Fasting Glucose | -30.87 ± 1.876 | -26.58 ± 1.871 |
Percentage of Time in glucose range between 70 and 180 mg/dL (3.9 and 10.0 mmol/L), inclusive measured during the continuous glucose monitoring (CGM) session.
| Percentage of time | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Percentage of Time in Glucose Range | 58.39 ± 0.993 | 57.05 ± 0.990 |
Percentage of Time in hypoglycemia range with glucose \<54 mg/dL (3.0 mmol/L), measured by CGM.
| Percentage of time | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Percentage of Time in Hypoglycemia Range | 6.84 ± 0.700 | 5.25 ± 0.680 |
Percentage of Time in hyperglycemia range with glucose \>180 mg/dL (10.0 mmol/L), measured by CGM.
| Percentage of time | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Percentage of Time in Hyperglycemia Range | 40.10 ± 1.024 | 41.60 ± 1.024 |
Glucose variability measured as coefficient of variation for glucose within day for 24-hour period between Week 22 and 26 was reported.
| Coefficient of Variation | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Glucose Variability Between Weeks 22 to 26 | 28.51 ± 0.259 | 28.28 ± 0.254 |
Average weekly basal Insulin Dose at Week 26 was reported.
| Units per week of basal insulin | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Basal Insulin Dose at Week 26 | 391.59 ± 7.482 | 426.62 ± 7.323 |
Average daily bolus Insulin Dose at Week 26 was reported.
| Units per day of bolus insulin | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Bolus Insulin Dose at Week 26 | 27.01 ± 1.182 | 34.56 ± 1.156 |
Average total weekly insulin dose at Week 26 was reported.
| Units per week of insulin | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Total Insulin Dose at Week 26 | 592.92 ± 12.560 | 666.43 ± 12.144 |
Basal insulin dose to total insulin dose ratio at Week 26 was reported.
| Ratio | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Basal Insulin Dose to Total Insulin Dose Ratio at Week 26 | 70.09 ± 0.749 | 66.55 ± 0.722 |
Hypoglycemia event rate was reported. Hypoglycemia with glucose \<54 mg/dL (Level 2) or Severe Hypoglycemia (Level 3) was reported. A severe hypoglycemic event is characterized by altered mental or physical status requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions for the treatment of hypoglycemia. Group mean was reported here.
| Events per year | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Hypoglycemia Event Rate | 6.58 ± 0.709 | 5.94 ± 0.618 |
Change from baseline in body weight was reported.
| kilograms (kg) | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Change From Baseline in Body Weight | 2.67 ± 0.165 | 2.53 ± 0.165 |
The DID-EQ is a self-administered, 10-item questionnaire designed to assess participants' perceptions of diabetes injection delivery systems for diabetes. The Device Characteristic Subscale is comprised of items 1 to 7 which focus on specific characteristics of injection devices. Each item is rated on a four-point Likert scale. Scores are transformed and range from 0 to 100. Higher scores indicate more positive perceptions of injection device characteristics
| Score on a scale | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| Treatment Experience for Diabetes Injection Device at Week 26 - Experience Questionnaire (DID-EQ) | 88.1 ± 0.77 | 86.3 ± 0.75 |
Collected over Baseline Through Safety Follow-Up (Up To 31 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 500 U/mL - Insulin Efsitora | 1/365 (0.3%) | 25/365 (6.8%) | 35/365 (9.6%) |
| 100 U/mL - Insulin Glargine | 1/365 (0.3%) | 24/365 (6.6%) | 40/365 (11%) |
| Event | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 5/365 | 5/365 |
| PneumoniaInfections and infestations | 3/365 | 1/365 |
| Cardiac arrestCardiac disorders | 2/365 | 0/365 |
| Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/193 | 0/176 |
| Acute myocardial infarctionCardiac disorders | 1/365 | 1/365 |
| Angina pectorisCardiac disorders | 1/365 | 0/365 |
| Arteriosclerosis coronary arteryCardiac disorders | 1/365 | 0/365 |
| Atrioventricular blockCardiac disorders | 1/365 | 0/365 |
| Cardiac failure congestiveCardiac disorders | 1/365 | 0/365 |
| Left ventricular failureCardiac disorders | 0/365 | 1/365 |
| Event | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine |
|---|---|---|
| NasopharyngitisInfections and infestations | 23/365 | 21/365 |
| InfluenzaInfections and infestations | 14/365 | 19/365 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine | Total |
|---|---|---|---|
| Mean | 58.3 ± 10.5 | 59.4 ± 10.5 | 58.9 ± 10.5 |
| Sex: Female, Male(Participants) | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine | Total |
|---|---|---|---|
| Female | 193 | 176 | 369 |
| Male | 172 | 189 | 361 |
| Ethnicity (NIH/OMB)(Participants) | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine | Total |
|---|---|---|---|
| Hispanic or Latino | 201 | 203 | 404 |
| Not Hispanic or Latino | 163 | 161 | 324 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 46 | 45 | 91 |
| Asian | 54 | 51 | 105 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 11 | 31 |
| White | 245 | 258 | 503 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine | Total |
|---|---|---|---|
| Argentina | 83 | 83 | 166 |
| Germany | 27 | 24 | 51 |
| India | 50 | 50 | 100 |
| Italy | 11 | 15 | 26 |
| Mexico | 85 | 84 | 169 |
| Spain | 35 | 35 | 70 |
| United States | 74 | 74 | 148 |
| HemoglobinA1c (HbA1c)(Percentage of HbA1c) | 500 U/mL - Insulin Efsitora | 100 U/mL - Insulin Glargine | Total |
|---|---|---|---|
| Mean | 8.17 ± 0.83 | 8.18 ± 0.79 | 8.18 ± 0.81 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Aug 2022 to primary completion in Feb 2024, 18 months.
Results were first posted in Apr 2025, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin efsitora alfa · Insulin Glargine